Immune responses to non-structural protein 3 (NS3) of bovine viral diarrhoea virus (BVDV) in NS3 DNA vaccinated and naturally infected cattle

Immune responses to non-structural protein 3 (NS3) of bovine viral diarrhoea virus (BVDV) were investigated. cDNA encoding NS3 from type 1a BVDV was used to vaccinate five calves, another five calves remained unvaccinated. Three weeks after final vaccination animals were challenged intranasally with heterologous type 1a BVDV. Anti-NS3 antibodies were detected in only one animal post-vaccination. Partial protection from virus challenge was observed in the vaccinates. Virus was not isolated from nasal mucosa of two vaccinates, and virus clearance from nasal mucosa was faster in the vaccinates compared to the controls. While elevated rectal temperatures were evident in both groups 7 days post-challenge, the mean increase in the controls was twice that observed in the vaccinates. In conclusion, NS3 DNA vaccination induced humoral immunity in one calf, and prevented fever and virus establishment in the nasal mucosa in 2/5 calves, demonstrating the efficacy of NS3 vaccination, which may benefit future development of pestivirus and flavivirus vaccines.     

Studies on immunisation of suckling calves with dictol

The immunisation of young milk-fed calves with two doses of the commercially available Dictyocaulus viviparus irradiated larval vaccine, Dictol, was studied. In the first experiment, vaccination of groups of pail-milk-fed calves at 3 and 7 weeks of age resulted in 96.7% reduction of lungworm burdens upon challenge when compared with non-vaccinated controls. Contemporaneous vaccination of calves aged 8 and 12 weeks resulted in a reduction in lungworm burden of 98.9% compared with controls of the same age. The clinical reaction upon challenge of both age groups was minimal compared with their respective controls.In the second experiment a group of six suckling calves were vaccinated with Dictol at 3 and 7 weeks of age and then challenged with infective larvae of D. viviparus together with non-vaccinated controls. At subsequent post-mortem examination the mean lungworm burdens of the vaccinates was 87% less than that of the controls. Some clinical reaction evidence by increased respiratory rates and bodyweight loss occurred in the vaccinates but this was not as severe as in the controls. At necropsy a concurrent pneumonia due to Mycoplasma spp. was present and it is suggested that this contributed to the poorer protection obtained compared with the pail-milk-fed calves of the fist experiment.In the third experiment a group of suckling calves were again vaccinated at 3 and 7 weeks of age and then exposed to a natural challenge together with parasite-naive controls. Although the level of challenge was relatively low, immunisation was apparently high successful as lungworms were completely absent in the vaccinates when examined at necropsy.In all three experiments numerous pulmonary lymphoid nodules, which are a useful guide to the immune status of calves, were present in the vaccinates and absent or scarce in the controls. It is concluded that the cumulative evidence from the three experiments suggest that immunisation against infections of D. viviparus of young milk-fed calves in the field may be a practical proposition.     

Comparison of a levamisole sustained-release bolus and ivermectin treatment to prevent bovine lungworm infection

The efficacy of a levamisole sustained-release bolus to prevent parasitic bronchitis in calves in their first grazing season was compared to ivermectin treatment at three, eight and thirteen weeks after turn out. Contamination of the pasture was established by experimentally infected seeder calves. Twenty calves were split into two groups. Ten calves of one group received a bolus at the start of the experiment. In the other group the calves were treated with ivermectin at 21, 56 and 91 days. Two principal calves from each group were killed during the experiment to study histopathological changes. Pairs of tracer calves were introduced on both pastures at intervals of four weeks throughout the grazing period. The permanent calves were challenged with lungworm larvae at housing and slaughtered four weeks later. Both systems prevented parasitic bronchitis. Larval output was completely reduced in the ivermectin-treated calves while all bolus-treated calves excreted larvae at certain times. The highest group average was 4 larvae per gram faeces. Eosinophilia, ELISA-titres and histopathological changes confirmed the differences in larval uptake. Challenge infection was not successful in either group and no worms were found at slaughter. Weight gain was significantly different at housing in favour of the ivermectin-treated calves, but after challenge this was reduced due to a higher weight gain in the bolus-treated calves. The practical consequences of the results have been discussed.     

A Controlled Field Study Using Live Virus Vaccines and an Antiserum in a Preconditioning Program

Thirty-five vaccinates and 29 control beef calves from five farms were studied. Vaccinates in group 1 received a modified live virus vaccine against infectious bovine rhinotracheitis (IBR) and bovine virus diarrhea (BVD) 30 days after shipment; vaccinates in groups 2, 3 and 4 received live virus vaccines agains IBR and bovine parainfluenza 3 (PI3) seven to 17 days before shipment. Half of group 5 were given bovine origin antiserum containing antibodies against IBR, BVD and PI3. Three weeks later, the animals that had received serum were given a live modified vaccine containing IBR, BVD and PI3. In group 1, WBC counts were lower in the vaccinates than in the controls for two weeks after vaccination. WBC counts in groups 3 and 4 were higher in vaccinates than in controls after addition to the feedlot. Seroconversions to BVD virus occured in all groups. Clinical disease apparently due to BVD affected one vaccinated calf in group 2 and eight calves in group 5. Combined weight gains were significantly higher in three groups of calves vaccinated before shipment compared to unvaccinated control animals after addition to the feedlot. Vaccination with IBR and PI3 live virus vaccines should be given at least 17 days before shipment to feedlots containing infected cattle. Antiserum containing antibodies against the three viruses showed no apparent advantage in preventing clinical respiratory disease over control calves not receiving the serum.     

The use of the morantel sustained release bolus under special farm practices (deprime system) in France

The efficacy of the morantel sustained release bolus in controlling gastrointestinal and lungworm parasites when used in first-season grazing animals which followed older animals onto spring pasture (deprime system) was assessed in three trials conducted in Normandy, France. In each trial first-season grazing calves were equally allocated onto two separate but equivalent paddocks where they remained throughout the grazing season. A morantel sustained release bolus was administered to one group of animals at turnout, the other group remained as controls. The effect of the treatment on contamination of pasture (herbage larval counts and tracer worm counts), on faecal worm egg and lungworm larval counts, and on weight gain performance of the principal animals was assessed. In all three trials, worm egg output in the bolus-treated animals was substantially lower throughout the season compared with the control animals. Worm burdens of tracer calves grazing pastures of the treated cattle were also reduced compared with tracer calves grazing control pastures. Clinical parasitic gastroenteritis occurred in the control animals but not in the bolus-treated animals in one trial. Overall the bolus-treated animals outperformed the controls by a mean weight gain advantage of 10.5 kg (P less than 0.01).     

Detection of bovine herpesvirus-1 in peripheral blood mononuclear cells eight months postinfection.

Peripheral blood mononuclear cells (PBMCs) from 5 calves (3 controls and 2 vaccinates) used in a bovine herpesvirus 1 (BHV-1) vaccine study with a BHV-1 Cooper strain challenge were collected 6 months after challenge. The PBMCs from the control animals were positive by immunofluorescence for the BHV-1 glycoprotein D (gD) while the vaccinates were negative. The PBMC samples from 4 of the 5 animals were examined for BHV-1 DNA by polymerase chain reaction (PCR) and for gD immunofluorescence at 8 months after challenge. The BHV-1 DNA and viral antigen were detected in PBMC samples at 8 months postinfection, but no virus was isolated.     

Vaccination of calves with Haemonchus placei intestinal homogenate

The ability of adult Haemonchus placei intestinal homogenate to confer protection against homologous challenge infection was evaluated. Calves were immunized twice with 100 microg H. placei intestinal protein in 5% dextran-sulfate/PBS (vaccinates) or PBS alone (controls) and were challenged with approximately 3300 infective H. placei larvae. There was no significant difference between groups in the total number of nematodes recovered but significantly fewer (p < 0.001) adult females were recovered from vaccinates. The proportion of fourth-stage larvae in vaccinates was significantly greater (p < or = 0.05) than in controls. Lengths of adult male and female nematodes were significantly shorter (p < 0.001) in vaccinated calves, and the numbers of eggs present in the uteri of female nematodes from vaccinates were significantly decreased (p < 0.001). Counts of nematode eggs per gram of feces (EPG) of vaccinates were significantly less than that for controls on Days 29-49 post-challenge (p < or = 0.05). Vaccinates had significant increases in serum IgG1 and IgG2 log(10) titers (p < or = 0.05) but not in serum IgM. EPG, numbers of females, and size of males and females were negatively correlated with increased mean post-challenge IgG1 and IgG2 titers. Reduction in binding of periodate-treated gut homogenate by immune serum indicated a carbohydrate specific component in the immune response.     

Comparison of vaccination and ivermectin treatment in the prevention of bovine lungworm

Three groups of calves were put out to graze on separate paddocks within a field known to be infected with Dictyocaulus viviparus and were also given a small initial trickle infection of the parasite. The first group were untreated controls, the second were immunised with live irradiated lungworm vaccine and the third were injected three times with ivermectin; the injections taking place after they had grazed for three, eight and 13 weeks. The subsequent infections of D viviparus were estimated by grazing a series of parasite-free tracer calves in the paddocks used by each group. The first group of such calves grazed from July 17 until August 7, the second from August 22 to September 29. During the first half of the grazing season all the untreated and three of the six immunised calves were observed to excrete D viviparus larvae, in contrast to none of the ivermectin-treated group. As a result all the tracer calves on the areas occupied by the untreated and immunised calves became infected with the parasite whereas only one worm was found in one of the 10 tracer calves grazing the area occupied by the ivermectin-treated calves.     

Effect of repeated doses of levamisole on grazing cattle infected with Dictyocaulus viviparus

Seventy-one worm-free Friesian calves were allocated by weight to three trial groups (1, 3 and 4) of 18 and a control group (2) of 17 animals. Calves in group 1 were vaccinated with a bovine lungworm oral vaccine on days 0 and 28, and on day 42 all groups were turned out to graze together on pasture known to be infected with Dictyocaulus viviparus larvae. Twenty-eight days after first exposure to infection one control calf died of parasitic bronchitis. Anthelmintic medication consisting of two doses of levamisole (7 . 5 mg/kg) at 14 day intervals was promptly administered to group 3 calves and three doses at the same intervals to group 4 calves. All calves were challenged with 20,000 infective D viviparus larvae on day 147. Calves were weighed every 14 days throughout the trial which ended 42 days after challenge. Pasture contamination and infectivity were monitored by pasture larval counts and tracer calves. Statistically there was no significant difference between the performances of treated and vaccinated groups before challenge but all were significantly superior to the control group. After challenge the productivity of all experimental groups was temporarily depressed but the levamisole treated cattle recovered more rapidly becoming significantly heavier than the vaccinates at the end of the trial. The mean group weight gains over the trial period were 89 . 92, 63 . 87, 88 . 67 and 98 . 70 kg in groups 1, 2, 3 and 4 respectively.     

Experimental Bovine Pneumonic Pasteurellosis II. Genesis and Prevention

Two experiments were conducted. In the first, 16 crossbred Hereford calves were divided into two equal groups. The first group was vaccinated intranasally with a commercial vaccine against bovid herpesvirus 1 and the second group was unvaccinated. The calves were later exposed to an aerosol of bovid herpesvirus 1 (strain 108) for five minutes. Four calves from each group were subjected to transportation and four calves from each group were kept in an environmental chamber for four days. Four days after viral aerosol all calves were exposed to an aerosol of Pasteurella haemolytica and the same subgroups were again transported or held in the chamber for a further four days.

The calves that did not die from pneumonia were necropsied ten days after the final day of transport. Pulmonary lesions were present in both vaccinated and control animals but were less extensive in the vaccinated calves. Six of eight vaccinated but none of the eight control calves survived.

In the second experiment, eight crossbred Hereford calves were divided into two equal groups. One group was vaccinated with bovid herpesvirus 1 (strain 108) and the other acted as controls. Four weeks later all calves were sequentially exposed to aerosols of bovid herpesvirus 1 (strain 108) and P. haemolytica four days apart. Three of the four controls but none of the vaccinates died from pneumonia. Every lobe of the lungs in all the controls was affected by pneumonia while no pulmonary lesions were found in the vaccinated calves. The differences in efficacy of the modes of vaccination and the possible role of transport stress are discussed.

     

Duration of immunity and efficacy of an oil emulsion Escherichia coli bacterin in cattle

An oil emulsion Escherichia coli bacterin administered in 1- and 2-dose vaccination regimens was evaluated in beef cattle. Serologic responses to the K99 pilus antigen were monitored, and suckling offspring from vaccinated and nonvaccinated cows were inoculated with virulent, K99-positive, enterotoxigenic Escherichia coli. The degree of protection and duration of immunity conferred were determined in 2 respective studies. In the first study (study A), titers of pregnant cattle were determined from time of vaccination through calving (a 6- to 20-week period). Titers of 24 cows vaccinated with a single 2-ml dose of bacterin were compared with those of 24 cows given a 2-dose regimen and with those of 23 nonvaccinated cattle (contemporary controls). Inoculum consisting of 1.2 X 10(12) viable enterotoxigenic E coli/dose administered to nursing calves from these dams yielded 0% mortality (0 deaths/20 calves) in calves from 1-dose vaccinates, 6% mortality (1 death/18 calves) in calves from 2-dose vaccinates, and 37% mortality (7 deaths/19 calves) in calves from nonvaccinated dams. Study B was an extended evaluation conducted in cattle that were kept in the study up to 87 weeks from initial vaccination until calving. Serologic titers to the K99 pilus antigen were compared in 1-dose, 2-dose, and nonvaccinated cattle in groups of 8, 6, and 6, respectively. Calves from these dams were inoculated with 8.1 X 10(11) viable enterotoxigenic E coli/dose, which resulted in 0% mortality (0 deaths/5 calves) in calves from 1-dose vaccinates, 0% mortality (0 deaths/5 calves) in calves from 2-dose vaccinates, and 80% mortality (5 deaths/6 calves) in calves from nonvaccinated dams.     

Experimental infections with Cooperia oncophora in calves. A study with two different larval dose levels and dosing regimens.

The effect of different larval dose level and dosing regimens on the course of Cooperia oncophora infection in calves was studied. Four groups each of 4 calves were experimentally infected either with 50,000 or 200,000 C. oncophora larvae (L3) given either as single infections or as daily trickle infections. An additional group of calves remained as uninfected controls. The animals were necropsied on week 4 after infection. Mild to moderate clinical signs of parasitic gastroenteritis developed among calves given high doses of larvae, but liveweight gains were not significantly different from those of the uninfected controls. Serum pepsinogen levels of dosed animals were within normal ranges but rose slightly, and on day 14 p.i. they differed significantly from those of the controls. On that occasion, the levels of serum pepsinogen in the trickle infected groups significantly exhibited the levels of the single infected groups. Hypoalbuminaemia was not a feature on any occasion. The various groups did not differ significantly with regard to total worm counts and adult worm counts, but the groups receiving high larval dose harboured significantly more fourth stage larvae than the group receiving low doses of larvae, both in terms of absolute counts and in terms of percentages of total worm burdens. Within the same dose level, there was a tendency of a more even distribution of worms along the small intestine when the infections was given as a single infection compared with a trickle infection. The results indicate that C. oncophora larval dose and dosing regimens may influence the pathogenic effects and to some extent the distribution of the parasite in the small intestine.     

Coronavirus infection in the laboratory rat: immunization trials using attenuated virus replicated in L-2 cells.

Sixty-nine specific pathogen-free male Wistar rats approximately eight weeks of age were used to evaluate the efficacy of an attentuated strain of sialodacryoadenitis (SDA) virus in providing protection against infection on subsequent challenge with virulent SDA virus. Fifty-four animals were inoculated intranasally with approximately 10(3.5) median cell culture infectious doses of the 25th passage of SDA virus in L-2 cells. Randomly-selected vaccinated animals were killed in order to evaluate the safety and efficacy of attenuated virus by histopathological examination of the salivary glands, lacrimal glands, and lower respiratory tract, and titration of sera for antibody to SDA virus. At three months and six months postvaccination (pv), animals were selected at random and challenged with virulent SDA virus. Seronegative, age-matched animals were also challenged, and served as controls. In animals examined at six to ten days pv, lesions were absent in submandibular and parotid salivary glands and lacrimal glands, but transient lesions were present in major airways of the lower respiratory tract. In a comparison of the incidence and extent of lesions, and antibody titers in challenged vaccinates and seronegative controls, lesions were minimal or absent in vaccinates compared to challenged naive rats, particularly in animals inoculated at three months pv. In addition, antibody titers in challenged vaccinates were much higher than were postinoculation titers in inoculated controls. In a comparison of lesions in salivary and lacrimal glands in vaccinated and control animals challenged at six months pv, there was a significant reduction in the number of animals without lesions in the vaccinated group (p = less than 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)     

Control of gastrointestinal strongylids in first year calves: use of Paratect Flex bolus at late pasture turnout]

The efficacy of the Paratect Flex-Bolus for the control of parasitic gastroenteritis in calves was evaluated in a field experiment in the Swiss midland region. The bolus was administered to 9 first year grazing calves at 4 to 5 months of age before turnout on June 26 while 9 calves remained as untreated controls. Both groups were rotated between 8 paddocks that had been pregrazed by older cattle in spring. For a period of 12 weeks the faecal egg output of the treated calves was reduced significantly (p < 0.05) compared to the controls, whereas no significant differences were observed in the mean serum pepsinogen values of both groups. At the end of the experiment (November 14) the bolus-treated calves showed a 4 kg weight gain advantage over the controls which was not significant. The mild infection levels in both groups were probably due to the low pasture contamination with infective larvae throughout the season which most likely resulted from the late turnout of the calves. An outbreak of dictyocaulosis was observed in both groups in October and confirmed that the Paratect Flex-Bolus provides insufficient protection against this infection.     

Efficacy of ivermectin administered via sustained-release bolus against gastrointestinal nematodes in cattle

Twelve calves (mean weight, 175.5 kg) were used to confirm efficacy of ivermectin delivered from a prototype sustained-release bolus against naturally acquired gastrointestinal nematodes including early fourth-stage (inhibited) larvae of Ostertagia ostertagi. The calves were allocated by restricted randomization on weight to 1 of 2 groups: controls, to which a placebo bolus was given orally, and treated calves, to which a sustained-release bolus designed to deliver 8 mg of ivermectin/day at a steady rate was given orally. After treatment, the 2 groups were housed in separate pens with concrete flooring. Twenty-eight days after treatment, all calves were euthanatized and necropsied. The ivermectin-treated calves had no larval or adult Ostertagia spp and significantly (P less than 0.01) fewer adult Trichostrongylus axei and adult Cooperia (C oncophora, C punctata and C surnabada) than control calves. Efficacy of ivermectin was greater than 99% for Cooperia spp, and 100% for other parasites. Drug-related adverse reactions were not observed.     

Serological Studies of Parasite Cattle: I. Complement-Fixing Activity of Serial Serum Samples

Complement-fixation (CF) tests with sonicated aqueous extracts of adult forms of five species of gastrointestinal nematodes as antigens have been made on serial biweekly bleedings from two groups of parasitized calves grazing on infected pastures during the 1963 or 1964 seasons. Three of these nematode species, Cooperia oncophora, Ostertagia ostertagi and Nematodirus helvetianus, were found in large numbers in most of these animals. The calves were negative serologically before being placed on pasture but within 2 to 4 weeks some had developed considerable CF activity with Cooperia and other nematode antigens. Ten calves died, however, before significant CF titres had been attained. Eight control calves in the 1963 or 1964 groups which were grazed on “clean” pastures, remained serologically negative during the summer and autumn months. Four of the six surviving exposed animals in the 1964 group showed a fall in CF activity during the winter months when they were stabled, whereas the six surviving controls developed low CF titres suggesting that they were becoming mildly parasitized. In the spring of 1965 CF titres began to rise in some of the previously exposed and control yearlings even before they were placed on infected pasture in June.     

Control of naturally acquired bovine parasitic bronchitis and gastroenteritis with an oxfendazole pulse release device

Four groups, each of six male Friesian calves, were set-stocked on separate 0.66 ha paddocks from May 7 until October 23 1986. Each of the animals in groups 1 and 4 was dosed with an oxfendazole pulse release bolus at turn out whereas the animals in groups 2 and 3 were left untreated. Parasite-free naive tracer calves were introduced into each paddock for a limited period 12 days after turn out and again at the end of the trial. No adverse reactions or clinical signs were observed in either of the groups of calves which received boluses. The development of clinical parasitic gastroenteritis in both the untreated groups necessitated the humane slaughter of two animals and emergency anthelmintic treatment of the remainder. The lower plasma pepsinogen concentrations, and lower faecal egg and larval counts and worm burdens post mortem, together with the absence of clinical signs of parasitic gastroenteritis and bronchitis in the treated calves, confirmed the high efficacy of the bolus treatment.     

Update on vaccination of cattle and wildlife populations against tuberculosis

A recombinant bovine herpesvirus 5 lacking thymidine kinase and glycoprotein E genes (BoHV-5gEΔTKΔ) was evaluated as a live experimental vaccine. In a first experiment, ten-months-old calves were vaccinated intramuscularly (n=9) or remained as controls (n=8) and 42 days later were challenged with BoHV-5 or BoHV-1 intranasally. The four control calves challenged with BoHV-5 developed severe depression and neurological signs and were euthanized in extremis at days 13 and 14 pos-infection (pi); the five vaccinated animals challenged with BoHV-5 remained healthy. The titers of virus shedding were reduced (p<0.01) from days 3 to 7 post-infection (pi) in vaccinated animals. Control and vaccinated calves challenged with BoHV-1 presented mild transient respiratory signs; yet the magnitude of virus shedding was reduced (p<0.05) in vaccinated animals (days 5, 9 and 11pi). In a second experiment, young calves (100-120 days-old) were vaccinated (n=15) or kept as controls (n=5) and subsequently challenged with a BoHV-1 isolate. Control calves developed moderate to severe rhinitis and respiratory distress; two were euthanized in extremis at days 5 and 9 pi, respectively. In contrast, vaccinated animals were protected from challenge and only a few developed mild and transient nasal signs. The duration and titers of virus shedding after challenge were reduced (p<0.05) in vaccinated animals comparing to controls. In both experiments, vaccinated animals developed antibodies to gE only after challenge. These results demonstrate homologous and heterologous protection and are promising towards the use of the recombinant BoHV-5gEΔTKΔ in vaccine formulations to control BoHV-5 and BoHV-1 infections.     

Field evaluation of the oxfendazole pulse release bolus for the chemoprophylaxis of bovine parasitic gastroenteritis: a comparison with three other control strategies

Three trials were conducted in southern England involving 120 autumn-born calves to evaluate the ability of an oxfendazole pulse-release intraruminal device (OPRB) to control parasitic gastroenteritis (PGE). Matched groups were set-stocked on adjacent paddocks. One group received an OPRB at turn-out; one was treated with an alternative chemoprophylactic programme; while the third acted as an untreated control. In each trial clinical PGE occurred in the latter group but not in OPRB or alternative strategy groups. The OPRB, the morantel sustained release bolus (MSRB) and fenbendazole administered at 3 and 6 weeks after turn-out gave similar weight-gain benefits when compared with untreated controls (P less than 0.01), but the growth rate of animals given regular levamisole treatments from July to housing was significantly poorer than the matching OPRB group (P less than 0.05) although better than controls. Faecal egg-output of OPRB calves was reduced by 97.0-99.9% compared with 95.5 and 58.9% for MSRB and fenbendazole treatments. Consequently, the late summer/autumn peaks in pasture larval counts were considerably reduced in all treatment groups other than the late-season levamisole strategy which reduced overall egg-output by only 37.6%. Serum pepsinogen and gastrin values confirmed a greater degree of abomasal disturbance in calves grazing on the more highly contaminated pastures. Incidental lungworm infections became clinically apparent in the control groups of two trials but not in any OPRB or alternative treatment group.     

Efficacy of low doses of fenbendazole and its administration via drinking water in the prophylaxis of nematodiasis in grazing calves

Under experimental conditions, fenbendazole given at doses of 0.4 and 1.0 mg/kg body weight suppressed calves' faecal output of Ostertagia and Cooperia species eggs and Dictyocaulus viviparus larvae. Both dose levels were given in the form of small daily drenches and the higher level showed greater efficacy. In a grazing experiment, medication with fenbendazole at 1.0 mg/kg/day administered intermittently to calves using an automatic dose dispenser almost completely suppressed the output of trichostrongylid eggs. As a result, infection on the pasture and in the calves remained at a low level throughout the grazing season. By contrast, control pasture and control calves showed rather heavy infection from mid-August onwards with significantly lower weight gains and widespread signs of parasitic gastroenteritis. At post mortem examination of representative calves from each group in November, the medicated animals had 99 per cent less Ostertagia species, whether adults or larvae arrested at the early fourth stage, and 95 per cent less Cooperia species compared with controls. Medication in the drinking water suppressed the faecal output of D viviparus larvae for most of the grazing season by comparison with the controls but the medicated calves became infected with this parasite towards the end of the season. Until this problem is overcome, precautions against parasitic bronchitis are advised when this system of medication is adopted.